Stem Cell Therapy vs Standard of Care in Cardiomyopathy (NCT02962661)

Randomized 3-Arm Trial with Standard of Care Alone vs either Intravenous Infusion or Transendocardial Injection of Allogeneic Bone Marrow-Derived Multipotent Mesenchymal Stromal Cells (MSCs) plus Standard of Care in Patients with Anthracycline-Associated Cardiomyopathy

To demonstrate the safety of allogeneic human mesenchymal stem cells (hMSCs) administered by intravenous infusion and transendocardial injection in patients with left ventricular (LV) dysfunction and heart failure secondary to chemotherapy with anthracyclines.

MDA Study PI: Amanda Olson, MD
THI PI: Emerson Perin, MD, PhD

SPONSOR: M.D. Anderson Cancer Center
COLLABORATOR: Texas Medical Center